In recent years, denosumab, a monoclonal antibody targeting RANKL, has been explored as a potential adjuvant therapy due to its ability to inhibit osteoclast activity, promote tumor mineralization, and reduce the likelihood of recurrence. The gene discussed is TNFSF11; the disease is neoplasm.